Fundraising FoxAN Venture Partners — Full Portfolio
12 tracked investments · listed companies and verified rows first
PAhR Therapeutics is a clinical-stage biotech company developing novel mechanisms to treat pulmonary arterial hypertension (PAH).
BiotechHealthtech
Co-investorsRA CapitalUTEC
Arterial equips existing municipal fleet vehicles with AI-enabled ARTIE units that inspect roads while driving normal routes, building a continuously updated GIS inventory of roadway assets, signage, and hazards.
AI & Machine LearningConstruction TechData & InfrastructureGovTechBoulder, US
Co-investorsTechstarsRA Capital
Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.
BiotechDeep TechLongevityPalo Alto, US
Amy Wang(PhD)inKenneth Horne(Executive Officer, Director)inDylan Morris(Director)inCristina Ghenoiu(Director)in
BoardTaro Inaba(Director)in
Co-investorsRemiges Ventures, Inc.Insight PartnersRA CapitalRDiscovery
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)Andy Orth(Chief Executive Officer)in
Co-investorsARCH Venture PartnersSofinnova VenturesViking GlobalAltitude Ventures Management, LlcCasdin CapitalFidelity Investments+5 more
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificNovo HoldingsFrazier Life SciencesLightstone VenturesLongwood Fund
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)inAlbert M. Kim(Chief Medical Officer)in
Co-investorsCatalio Capital Management, LPRA CapitalSanofi VenturesSV Health InvestorsCatalio Capital Management
Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.
BiotechHealthtech
Co-investorsCure VenturesThe Column Group
Typewriter Therapeutics develops mRNA-based gene therapies using a platform for targeted insertion of therapeutic genes, building on transposon research from the University of Tokyo.
BiotechDeep TechHealthtechTokyo, JP
Jun Zhou, PhD(Founder & Vice President, Discovery and Global Operations)Haruhiko Fujiwara, PhD(Founder & Advisor · Professor Emeritus, University of Tokyo)Tom Eickbush, PhD(Co-founder & Advisor · Professor Emeritus, University of Rochester)Kei Endo, PhD(Co-founder & Advisor · Associate Professor, University of Tokyo)Jim Collins, PhD(Co-founder & Advisor - Professor, MIT)Matthew Stanton, PhD(Chief Executive Officer)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Crystalys TherapeuticsPAhR TherapeuticsTortugas NeuroscienceTypewriter Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.